Martha Geoffrey sold $4.8M of MDT

Martha Geoffrey (Chairman and CEO) sold 50,000 shares of Medtronic plc (MDT) at $95.00 ($4.75M total) on 2026-10-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Martha Geoffrey
Published Oct 16, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MDT
Bearish
medium confidence
Mentioned
$MDT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDTBearishLow
01

Why it matters

The disclosed sale adds new information about Medtronic's leadership holdings, which can affect short‑term price dynamics.

02

Market read

The filing provides fresh data on insider holdings, a factor many traders monitor for potential price moves.

03

What to watch

Potential tax planning or diversification needs of the insider are not disclosed.

Relevance 5/10Novelty 8/10Timing: after‑hours filing

Background

Form 4 filings are primary disclosures of insider transactions and are used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$MDTBearishMedium confidence
Context

CEO Martha Geoffrey sold 50,000 Medtronic shares for $95 each, a $4.75M open‑market sale filed on Form 4.

Expected impact

likely slight downward pressure as investors digest the sell‑off

Evidence & confidence

A $4.75M sale by the chairman/CEO is material for a mid‑cap medical device company and often triggers short‑term selling.

Market effects

May prompt scrutiny of other medical‑device stocks for insider activity.

Limited to U.S. equities; no broader regional effect.

Minimal; only relevant to investors tracking Medtronic.

Counterpoint

The sale could be a routine liquidity event unrelated to company outlook.

Key entities

  • Martha Geoffrey

    Chairman and CEO of Medtronic plc

  • Medtronic plc

    Global medical‑device manufacturer (ticker MDT)

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MDTMed

Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system

Medtronic (NYSE: MDT) received FDA clearance for its Hugo™ robotic-assisted surgery system to perform general surgery procedures, including cholecystectomy and hernia repairs. The expansion covers 3.5 million annual U.S. surgeries. The system's modular design offers flexibility, and Medtronic aims to surpass 50,000 procedures globally by its fiscal year-end.

$MDTMedAI 8/10

Medtronic buys Contego Medical for $380 M, expanding access to next-generation carotid therapies

Medtronic plans to acquire Contego Medical for $380 million, expanding its carotid artery disease treatment portfolio. The deal includes Contego's FDA-approved Neuroguard IEP™ Direct System. Medtronic expects the acquisition to be minimally dilutive to adjusted EPS in FY27 and FY28, and neutral to accretive thereafter. The transaction is subject to closing conditions and expected to complete in Q3 FY25.

$MDTMedAI 9/10

Medtronic agrees to buy carotid stent maker Contego Medical for $380 million

Medtronic agreed to acquire Contego Medical for $380 million, with potential additional payments. The deal includes Contego's Neuroguard IEP Direct System and Excipio thrombectomy devices. Medtronic expects the acquisition to close in its fiscal third quarter, with minimal EPS dilution in fiscal 2027 and 2028, and a neutral to accretive effect afterward. Contego's devices focus on carotid artery disease and peripheral thrombectomy.